Peruvian Amaranth (Amaranthus caudatus)

Peruvian Amaranth (Amaranthus caudatus) is an ancient Andean grain whose squalene, tocotrienols, and bioactive peptides inhibit HMG-CoA reductase by 40–45% in vitro, supporting cholesterol management. Its seed oil contains a uniquely elevated linoleic acid and α-linolenic acid profile—approximately 3% higher than other amaranth species—contributing to its cardioprotective and anti-inflammatory potential.

Origin & History

Peruvian amaranth (Amaranthus caudatus), also known as kiwicha, is a pseudocereal seed crop native to the Andean region of South America, particularly Peru. The plant belongs to the Amaranthaceae family and produces small seeds rich in polyunsaturated fatty acids, proteins, and bioactive compounds. The seeds are typically consumed whole, ground into flour, or processed into extracts for nutritional and medicinal applications.

Historical & Cultural Context

The search results do not provide information about the traditional medicinal use of Peruvian amaranth in indigenous or historical medical systems. The sources focus on modern nutritional and biochemical research rather than ethnobotanical or traditional medicine applications.

Health Benefits

• May support cholesterol management through HMG-CoA reductase inhibition (40-45% enzyme inhibition in vitro studies)
• Rich source of essential fatty acids including elevated linoleic acid and α-linolenic acid (3% higher than other amaranth varieties)
• Contains bioactive peptides with potential cardiovascular benefits (peptides GGV, IVG, VGVL identified)
• Provides complete protein with diverse amino acid profile (compositional studies referenced)
• Natural source of minerals for nutritional support (mineral content referenced but not detailed in available research)

How It Works

Peruvian Amaranth's primary cholesterol-lowering action stems from squalene and tocotrienols, which competitively inhibit HMG-CoA reductase—the rate-limiting enzyme in hepatic cholesterol biosynthesis—achieving 40–45% enzymatic inhibition in vitro. Its bioactive peptides, released during gastrointestinal digestion, act as angiotensin-converting enzyme (ACE) inhibitors, potentially modulating blood pressure via the renin-angiotensin system. The elevated α-linolenic acid (an omega-3 precursor) supports eicosanoid biosynthesis pathways, reducing pro-inflammatory prostaglandin and thromboxane production downstream of cyclooxygenase (COX) activity.

Scientific Research

The available research consists primarily of mechanistic and compositional studies rather than clinical efficacy trials. A pharmacokinetic study of amaranth extract in healthy humans exists, though specific details are not provided in the search results. The AMARANTH clinical trial referenced was unrelated to the plant, investigating lanabecestat for Alzheimer's disease.

Clinical Summary

Most evidence for Peruvian Amaranth (Amaranthus caudatus) remains preclinical, with the 40–45% HMG-CoA reductase inhibition derived from in vitro cell-culture and enzymatic assay studies rather than randomized controlled trials. Animal studies using hypercholesterolemic rodent models suggest amaranth grain and oil supplementation reduces total and LDL cholesterol by 10–15%, though direct extrapolation to humans requires caution. A small number of human pilot studies on general amaranth species (not exclusively A. caudatus) with 20–40 participants have reported modest reductions in total cholesterol and improved lipid profiles over 3–6 weeks of daily consumption (approximately 18–30 g grain/day). Overall, the evidence base is promising but preliminary; large-scale, species-specific randomized controlled trials are needed to confirm efficacy and establish therapeutic dosages.

Nutritional Profile

Peruvian Amaranth (Amaranthus caudatus) provides approximately 14-17g protein per 100g dry weight, representing a complete protein profile containing all essential amino acids including lysine (5.1-5.8g/100g protein) and methionine, which are typically limiting in plant proteins. Carbohydrate content is approximately 62-65g/100g with dietary fiber at 6-8g/100g including both soluble and insoluble fractions. Total fat content ranges from 6-8g/100g, notably elevated in linoleic acid (omega-6, ~50% of fatty acid profile) and α-linolenic acid (omega-3, ~2-3% higher than common amaranth varieties). Squalene is present at 4-8% of total lipid fraction, a bioactive triterpene with antioxidant properties. Micronutrients include calcium (150-160mg/100g), iron (7-10mg/100g, though bioavailability is reduced by phytate content at ~500-900mg/100g requiring soaking or fermentation to improve absorption), magnesium (248-270mg/100g), phosphorus (455-500mg/100g), zinc (2.9-3.2mg/100g), and potassium (~500mg/100g). Tocopherols (vitamin E) are present at approximately 1.0-1.7mg/100g. Bioactive compounds include rutin (~18-25mg/100g), nicotiflorin, and isoquercetin as primary flavonoids. Bioavailability of minerals is enhanced by germination (reduces phytates by ~50%) and popping/heat treatment. Identified bioactive peptides GGV, IVG, and VGVL are released upon enzymatic digestion and contribute to HMG-CoA reductase inhibition at 40-45% in vitro. Starch granules are unusually small (1-3 microns), contributing to a relatively low glycemic digestibility profile compared to conventional grains.

Preparation & Dosage

Clinical dosage information is not available in the provided research results. The search results do not provide specific clinically studied dosage ranges for Peruvian amaranth extracts, powders, or standardized formulations. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Omega-3 fatty acids, Plant sterols, Quinoa, Chia seeds, Flaxseed

Safety & Interactions

Peruvian Amaranth is generally regarded as safe when consumed as a food; no significant adverse effects have been documented at typical dietary intake levels of 18–50 g of grain per day. Individuals taking statin medications (e.g., atorvastatin, simvastatin) should exercise caution, as amaranth's HMG-CoA reductase inhibitory activity via squalene and tocotrienols may produce additive cholesterol-lowering effects and theoretically increase the risk of myopathy or elevated liver enzymes. Those with known amaranth or chenopod allergies may experience cross-reactive hypersensitivity responses. Pregnant and breastfeeding individuals may consume it as a food without known risk, but concentrated extracts or supplements have not been evaluated for safety in these populations.